You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Baxter
Merck
Express Scripts
McKinsey

Last Updated: April 1, 2020

DrugPatentWatch Database Preview

Litigation Details for Reliant Pharmaceuticals Inc. v. Par Pharmaceuticals Inc. (D. Del. 2006)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Reliant Pharmaceuticals Inc. v. Par Pharmaceuticals Inc. (D. Del. 2006)

Docket   Start Trial Date Filed 2006-12-19
Court District Court, D. Delaware Date Terminated 2009-04-17
Cause 35:271 Patent Infringement Assigned To Joseph James Farnan Jr.
Jury Demand Defendant Referred To
Parties PAR PHARMACEUTICALS INC.; RELIANT PHARMACEUTICALS INC.
Patents 4,389,393; 5,446,070; 5,552,394; 5,681,588; 6,001,588; 7,553,239; 8,084,039
Attorneys Gerald J. Flattmann , Jr.; Jack B. Blumenfeld; James K. Stronski; John G. Taylor; Josy W. Ingersoll; Karen L. Pascale; Maryellen Noreika
Firms Morris, Nichols, Arsht & Tunnell; Young, Conaway, Stargatt & Taylor LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Reliant Pharmaceuticals Inc. v. Par Pharmaceuticals Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in Reliant Pharmaceuticals Inc. v. Par Pharmaceuticals Inc.

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Reliant Pharmaceuticals Inc. v. Par Pharmaceuticals Inc. (D. Del. 2006)

Date Filed Document No. Description Snippet Link To Document
2008-01-07 140 Letter validity, enforceability, or scope of U.S. Patent 5,552,394, and l did not investigate the validity, enforceability…products as well as the associated patents to those products The ‘394 patent, the subject of the current litigation…infringement of the ‘394 patent Watson denies this allegation and submits that the ‘394 patent is invalid. The …why it pulled the patent’s file wrapper - it did so to provide a summary ot` the patent’s factual history…review the ‘394 patent, it does not go so far as to indicate that Kenyon opined upon the patent’s validity External link to document
2008-01-24 150 Motion for Issuance of Letters Rogatory named inventors of the patent-in-suit, U.S. Patent No. 5,681,588 (“the ’588 patent”). Knoll Aktiengesellschaft…U.S. corporations. The patent-in-suit, U.S. Patent No. 5,681,588 (“the ’588 patent”), issued to Knoll Aktiengesellschaft…Topic No. 5: The Inventions Claimed in U.S. Patent No. 5,681,588 These questions are important …the ’287 patent”). Par believes that the ’287 patent—which was not disclosed to the U.S. Patent and Trademark…of the patent application that issued as U.S. Patent No. 5,581,588, or the ‘588 patent? 29. External link to document
2008-01-25 156 Order on Motion for Issuance of Letters Rogatory .S. corporations The patent-in-suit, U.S. Patent No. 5,681,588 (“the ’588 patent”), issued to Knoll Aktiengesellschaft…named inventors of the patent-in-suit, U.S. Patent No. 5,681,588_(“the ’588 patent”). Knoll Aktiengesellschaft…opic Noi 5: The Inventions Claimed in U.S. Patent No. 5,681,588 These questions are important to determining…prosecution of the patent application that issued as U.S. Patent No. 5,581,588, or the ‘588 patent? ls that your…subject patent is assigned, to enforce proper protection of the patent? Are you aware that the patent that External link to document
2008-01-25 157 Order on Motion for Issuance of Letters Rogatory named inventors of the patent-in-suit, U.S. Patent No. 5,681,588 (“the\’SSS patent”). Knoll Alctiengesellschat…U.S. corporations The patent-in-suit, U.S. Patent No. ` 5 681 588 (“the ’588 patent”), issued to Knoll … The-Inv_entions Claimed in U.S._ Pat_ent No. 5,681,588_6 -The_se questions are importantto determining…the ’287 patent”). Par believes that the ’287 patent-which Was not disclosed to the U.S. Patent and Trademark…prosecution of the patent application that issued as U.S. Patent No. 5,581,`588,- or the ‘588 patent? Is that External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Colorcon
AstraZeneca
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.